Common use of Financial Consideration Clause in Contracts

Financial Consideration. The Sponsor agrees to pay to the VHIO as the entity that manages the research process of the Oncology, Medical Hematology and Radiation Oncology Service of the HUVH and to the VHIR, as the entity managing the research of the HUVH, the amounts established in the Economic Report in accordance with the provisions of this Annex. Any modification of the budget contained in the Financial Budget must be mutually agreed to by the Parties. The amounts indicated in the Financial Budget will accrue VAT corresponding to the Sponsor's account, if applicable, according to current regulations The Sponsor will pay to VHIR the amount corresponding to sections E, F and H of the Economic Report in order to satisfy the foundational purposes of VHIR (promotion of Biomedical Research, Innovation and Teaching of HUVH). The Sponsor will pay the VHIO the amount corresponding to the remaining sections of the Economic Report in order to meet the costs of the Trial. The billing will take into account the number of patients included or recruited in the Trial, independently if they complete the treatment or if they do not complete it, so that the amount to be paid by the Sponsor will be proportionally modified to always guarantee compensation for total services actually provided. In the event that remote monitoring is carried out, in accordance with the provisions of Clause 14 and in order to cover the additional costs incurred by VHIO for the management of remote monitoring, the Sponsor shall pay VHIO an amount of €50 plus VAT per day of monitoring within the framework of this Trial. Compensation will be based as set forth in the patient visit log and case application forms ("CRF"). In the exceptional case that the Sponsor does not provide the Product directly (being this possibility previously accepted by HUVH and VHIO), the payment of the same will be governed by the following conditions: VHIO will invoice the medication according to the official RRP of each unit (each vial/bottle/box) at the time of reimbursement, adding to the same an amount of €150 per invoice as Pharmacy Service costs. A percentage of 10% will be additionally applied to these costs, in order to adequately cover the management costs incurred by VHIO for these items. The Sponsor shall pay the VHIR the amount of €1,500 for administrative, start-up and trial management costs. The Sponsor will pay VHIO the amount of €1,500 for the start-up costs of the Study in the Oncology/Hematology Department and an amount of €1,000 for the start-up of the Trial by the Pharmacy Department. These initial one-time payments will also be reflected in the Financial Report attached in this Annex, and will be invoiced with the signing of the Contract without being conditioned to the effective performance of the Trial or its approval by the ECRm or the AEMPS. The travel, accommodation and subsistence expenses of the patients will be managed through a service company designated by the Sponsor. The HUVH, VHIR and VHIO will be exempt from any type of management and / or processing of patient reimbursements during the Trial. In case of audit of the Trial by the Sponsor, the Sponsor shall pay VHIO the amount of 500 € per day for each day of the audit visit to compensate the costs incurred by the VHIO in the preparation, conduct and subsequent follow-up of the audit. This amount will not be applicable to regulatory agency inspections.

Financial Consideration. The Sponsor agrees to pay to the VHIO VHIR, as the entity that manages the research process of the Oncology, Medical Hematology and Radiation Oncology Service of the HUVH and to the VHIR, as the entity managing the research of the HUVHresearch, the amounts established in the Economic Report Financial Budget in accordance with the provisions of instalments established in this Annex. Annex I. Any modification of the budget contained in the Financial Budget must be mutually agreed to by the Parties. The amounts indicated in the Financial Budget will accrue VAT corresponding to the Sponsor's account, if applicable, according to current regulations The Sponsor will pay to the VHIR the amount corresponding to the sections E“Internal Costs - Tests”, “Internal Costs - Visits” and “Other Costs” specified in the Financial Budget (hereinafter, “Costs”). The Sponsor will pay the amount resulting from applying the percentages established in section D, section E and section F and H of the Economic Report in order Financial Budget, on the total basis of the Costs. This amount is intended to satisfy meet the foundational purposes of VHIR (promotion of Biomedical Research, Innovation and Teaching of HUVH). The Sponsor will pay the VHIO the amount corresponding to the remaining sections ) or medication management of the Economic Report in order to meet the costs of the TrialPharmacy Service. The billing will take into account the number of patients included or recruited in the Trial, independently if they complete the treatment or if they do not complete it, so that the amount to be paid by the Sponsor will be proportionally modified to always guarantee compensation for total services actually provided. In the event that remote monitoring is carried out, in accordance with the provisions of Clause 14 and in order to cover the additional costs incurred by VHIO VHIR for the management of remote monitoring, the Sponsor shall pay VHIO VHIR an amount of €50 plus VAT per day of monitoring within the framework of this Trial. Compensation will be based as set forth in the patient visit log and case application forms ("CRF"). In The Sponsor will pay the exceptional case that VHIR the Sponsor does not provide the Product directly (being this possibility previously accepted by HUVH and VHIO), the payment extraordinary costs referred to in section G of the same will be governed by the following conditions: VHIO will invoice the medication according to the official RRP of each unit (each vial/bottle/box) at the time of reimbursementFinancial Budget. The percentage established in section H, adding to the same an amount of €150 per invoice as Pharmacy Service costs. A percentage of 10% %, will be additionally applied to these costs, in order to adequately cover the management costs of said items incurred by VHIO for these itemsthe VHIR. The Sponsor shall pay the VHIR the amount of €1,500 for administrative, start-up and trial management costs. The Sponsor will pay VHIO the amount of €1,500 for the start-up costs of the Study in the Oncology/Hematology Department and an amount of €1,000 for the start-up of the Trial by the Pharmacy Department. These This initial one-time payments single payment will also be reflected in the Financial Report attached Budget in this AnnexAnnex I, and will be invoiced billed with the signing of the Contract without being conditioned to the effective performance realization of the Trial Test or its to the approval of it by the ECRm or the AEMPS. The travel, accommodation and subsistence expenses of the patients will be managed through a service company designated by the Sponsor. The HUVH, and the HUVH and VHIR and VHIO will be exempt from any type of management and / or processing of patient reimbursements during the Trial. In case of audit of the Trial by the Sponsor, the Sponsor shall pay VHIO the amount of 500 € per day for each day of the audit visit to compensate the costs incurred by the VHIO in the preparation, conduct and subsequent follow-up of the audit. This amount will not be applicable to regulatory agency inspections.

Financial Consideration. The Sponsor agrees to pay to the VHIO VHIO, as the entity that manages the research process of the Oncology, Medical Hematology and Radiation Oncology Service of the HUVH and to the VHIR, as the entity managing the research of the HUVHresearch, the amounts established in the Economic Report Financial Budget in accordance with the provisions of instalments established in this Annex. Any modification of the budget contained in the Financial Budget must be mutually agreed to by the Parties. The amounts indicated in the Financial Budget will accrue VAT corresponding to the Sponsor's account, if applicable, according to current regulations The Sponsor will pay the VHIR the amount corresponding to the sections “Internal Costs - Tests”, “Internal Costs - Visits” and “Other Costs” specified in the Financial Budget (hereinafter, “Costs”). The Sponsor will pay to VHIR the amount corresponding to sections E, F and H of the Economic Report in order to satisfy the foundational purposes of VHIR (promotion of Biomedical Research, Innovation and Teaching of HUVH). The Sponsor will pay to the VHIO the amount corresponding to the remaining sections of the Economic Report in order to meet satisfy the costs of the Trial. The billing will take into account the number of patients included or recruited in the Trial, independently if they complete the treatment or if they do not complete it, so that the amount to be paid by the Sponsor will be proportionally modified to always guarantee compensation for total services actually provided. In the event that remote monitoring is carried out, in accordance with the provisions of Clause 14 and in order to cover the additional costs incurred by VHIO for the management of remote monitoring, the Sponsor shall pay VHIO an amount of €50 plus VAT per day of monitoring within the framework of this TrialStudy. Compensation will be based as set forth in on the provisions of the patient visit log record and case application report forms ("CRF"). In the exceptional case that the Sponsor does not provide the Product directly (being this possibility previously accepted by HUVH and VHIO), the payment of the same will be governed by the following conditions: VHIO will invoice the medication according to the official RRP of each unit (each vial/bottle/box) at the time of reimbursement, adding to the same an amount of €150 per invoice as Pharmacy Service costs. A percentage of 10% will be additionally applied to these costs, in order to adequately cover the management costs incurred by VHIO for these items. The Sponsor shall pay the VHIR the amount of €1,500 for administrative, start-up and trial Study management costs. The Sponsor will pay VHIO the amount of €1,500 for the start-up costs of the Study study in the Oncology/Hematology Department and an amount of €1,000 for the start-up of the Trial study by the Pharmacy Department. These This initial one-time payments single payment will also be reflected in the Financial Report attached Budget in this Annex, and will be invoiced billed with the signing of the Contract without being conditioned to the effective performance realization of the Trial Test or its to the approval of it by the ECRm or the AEMPS. The travel, accommodation and subsistence expenses of the patients will be managed through a service company designated by the Sponsor. The HUVH, VHIO and VHIR and VHIO will be exempt from any type of management and / or processing of patient reimbursements during the TrialStudy. In case of audit of the Trial Study by the Sponsor, the Sponsor shall pay VHIO the amount of €500 € per day for each day of the audit visit to compensate for the costs incurred by the VHIO in the preparation, conduct and subsequent follow-up of the audit. This amount will not be applicable to regulatory agency inspections.